Neovascular glaucoma (NVG) is a severe, vision-threatening condition characterized by the growth of new, abnormal blood vessels on the iris and the drainage angle of the eye. These new vessels can block the normal outflow of aqueous humor, leading to increased intraocular pressure (IOP) and subsequent damage to the optic nerve. This condition often arises secondary to ischemic retinal diseases, such as diabetic retinopathy and central retinal vein occlusion, which result in retinal hypoxia and the upregulation of vascular endothelial growth factor (VEGF). Effective management of NVG requires a comprehensive approach that addresses both the elevated IOP and the underlying retinal ischemia. Two primary laser treatments for NVG are Cyclophotocoagulation (CPC) and Panretinal Photocoagulation (PRP). This article provides a detailed comparison of these techniques, discussing their mechanisms, efficacy, and potential side effects.

Pathophysiology

Neovascular glaucoma develops as a response to severe retinal ischemia. Ischemia leads to the release of VEGF, a potent angiogenic factor that stimulates the formation of new blood vessels. In NVG, these vessels grow on the iris (rubeosis iridis) and into the anterior chamber angle, obstructing the trabecular meshwork. This obstruction prevents normal aqueous humor outflow, causing a significant rise in IOP. Persistent elevation of IOP can lead to optic nerve damage and irreversible vision loss if not promptly managed.

Symptoms and Diagnosis

Symptoms of NVG can vary but often include:

• Severe eye pain: Due to the elevated IOP.
• Redness: Inflammation and congestion of the conjunctival vessels.
• Decreased vision: Resulting from corneal edema and optic nerve damage.
• Halos around lights: Caused by corneal edema.
• Photophobia: Sensitivity to light.

Diagnosis involves several key steps:

• Gonioscopy: To examine the drainage angle and identify neovascularization.
• Tonometry: To measure IOP.
• Slit-lamp examination: To visualize new blood vessels on the iris and detect signs of inflammation.
• Fundoscopy: To examine the retina for ischemia and new vessels.
• Fluorescein angiography: An imaging technique that helps identify areas of retinal ischemia and neovascularization.

Mechanism of Action

Cyclophotocoagulation targets the ciliary body, which produces aqueous humor, the fluid that maintains IOP. By applying laser energy to the ciliary processes, CPC reduces aqueous humor production, thereby lowering IOP. The laser induces coagulative necrosis of the ciliary epithelium, reducing the secretion of aqueous humor.

Types of CPC

1. Transscleral CPC (TSCPC): The laser is applied externally through the sclera (the white part of the eye). TSCPC uses a diode laser that penetrates the sclera to reach the ciliary body.
2. Endoscopic CPC (ECP): This technique uses an endoscope to visualize and directly apply the laser to the ciliary body from inside the eye. ECP allows for more precise targeting and reduced risk of overtreatment.

Efficacy and Outcomes

Studies have shown that CPC is effective in reducing IOP in patients with NVG, particularly those who have not responded to other treatments. TSCPC, while effective, carries a higher risk of complications such as hypotony (excessively low IOP), phthisis bulbi (shrinkage of the eye), and inflammation. ECP, being more targeted, tends to have fewer side effects and better outcomes. Additionally, recent advances in laser technology and techniques have improved the safety and efficacy of CPC.

Side Effects

• Inflammation: Post-procedural inflammation is common and may require anti-inflammatory medications.
• Hypotony: Over-reduction of IOP can lead to dangerously low pressure within the eye, potentially causing further complications.
• Pain: Some patients experience pain after the procedure, which can typically be managed with medications.
• Potential loss of vision: If the ciliary body is overtreated, it can lead to a significant reduction in IOP, causing hypotony and associated vision loss.

Mechanism of Action

Panretinal photocoagulation involves applying laser burns to the peripheral retina. This reduces the retina’s oxygen demand and subsequently decreases the production of VEGF, the protein responsible for promoting neovascularization. By reducing VEGF levels, PRP helps to regress neovascularization and prevent further growth of abnormal blood vessels.

Procedure

PRP is performed using an argon or diode laser. The procedure involves:

• Pre-treatment preparation: Topical anesthetic drops are applied to numb the eye. In some cases, a retrobulbar or peribulbar block may be used for deeper anesthesia.
• Laser application: Multiple laser spots are applied to the peripheral retina in a grid-like pattern, sparing the macula to preserve central vision. This may require several sessions to cover the entire peripheral retina adequately.

Efficacy and Outcomes

PRP is a well-established treatment for conditions leading to NVG, particularly diabetic retinopathy and retinal vein occlusion. It effectively regresses neovascularization, stabilizes IOP, and preserves vision. However, the full effect may take several weeks to become apparent, and repeat treatments may be necessary. PRP has also been shown to reduce the risk of severe vision loss in patients with proliferative diabetic retinopathy.

Side Effects

• Decreased peripheral vision: The laser burns can cause permanent loss of peripheral vision, which can affect activities such as driving.
• Night vision difficulties: Patients may experience difficulty seeing in low-light conditions due to the loss of rod photoreceptors in the treated areas.
• Macular edema: Swelling in the central part of the retina can occur, potentially affecting central vision.
• Potential exacerbation of existing retinal conditions: In some cases, PRP can worsen conditions like proliferative diabetic retinopathy if not carefully managed.

Efficacy

• CPC: Often reserved for refractory cases of NVG where IOP remains uncontrollable with other treatments. It provides a more immediate reduction in IOP. CPC can be particularly beneficial in cases where rapid IOP control is critical to preserving vision.
• PRP: Addresses the underlying cause of neovascularization, offering a more sustainable solution by reducing VEGF production. It is usually the first-line treatment in ischemic retinal conditions. PRP not only helps to control IOP indirectly by reducing neovascularization but also addresses the root cause of retinal ischemia.

Safety and Side Effects

• CPC: Higher risk of complications such as hypotony and inflammation due to the direct destruction of ciliary body tissues. However, advancements in CPC techniques, such as micropulse CPC, have aimed to reduce these risks by delivering laser energy in a controlled manner.
• PRP: Fewer severe side effects but can cause loss of peripheral vision and other visual disturbances. PRP is generally considered safer in terms of maintaining overall ocular health and function, though it may require multiple sessions for optimal results.

Patient Selection

• CPC: Preferable for patients with advanced NVG unresponsive to medical management and where rapid IOP reduction is necessary. CPC is also an option for patients who cannot undergo or have not benefited from other surgical interventions.
• PRP: Suitable for patients with underlying retinal ischemia and early to moderate NVG, especially when preservation of visual function is a priority. PRP is typically the first choice in managing the ischemic component of NVG, especially in diabetic patients.

Combination Therapy

In many cases, a combination of both CPC and PRP may be used to manage NVG effectively. PRP can address the underlying retinal ischemia and reduce VEGF levels, while CPC can provide additional IOP control. This combination approach can offer comprehensive management of NVG, addressing both the cause and the symptoms of the disease. The synergistic effect of both treatments can lead to better overall outcomes in terms of IOP control and preservation of vision.

Both Cyclophotocoagulation and Panretinal Photocoagulation play crucial roles in the management of neovascular glaucoma. The choice between CPC and PRP depends on the stage of NVG, the underlying cause, and the patient’s overall ocular health. PRP is generally preferred for its ability to target the root cause of neovascularization with fewer severe complications, while CPC serves as an effective option for refractory cases requiring rapid IOP reduction. Collaborative decision-making involving ophthalmologists and patients is essential to optimize treatment outcomes and preserve vision in NVG. Ongoing research and advancements in laser technologies and therapeutic approaches continue to improve the prognosis for patients with this challenging condition.

World Eye Care Foundation’s eyecare.live brings you the latest information from various industry sources and experts in eye health and vision care. Please consult with your eye care provider for more general information and specific eye conditions. We do not provide any medical advice, suggestions or recommendations in any health conditions.